Anthem Biosciences IPO IPO

Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes. The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale. The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery. As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules). As of September 30 and March 31, 2024, the company had over 425 and 550 customers in our CRDMO and specialty i

Anthem Biosciences Ltd. AddressNo.49, F1 & F2, Canara Bank RoadBommasandra Industrial Area, Phase 1BommasandraBengaluru, Karnataka, 560099+91 080 6672 400investors.abl@anthembio.comVisit Website